SCHEMBL19781619

SCHEMBL19781619

CC(C)Oc1ccc(-n2ccc3ccc(Br)cc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 1/20 0.41
CDK2 P24941 1/20 0.41
MAP3K14 Q99558 1/20 0.41
PIM3 Q86V86 1/20 0.40
FGFR1 P11362 1/20 0.38
BRD4 O60885 1/20 0.37
BRPF1 P55201 1/20 0.37
KMT2A Q03164 1/20 0.36
HTR7 P34969 2/20 0.36
HRH4 Q9H3N8 1/20 0.35
TFPI2 P48307 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
PRMT5 O14744 1/20 0.34
IDH1 O75874 1/20 0.34
CYP11B2 P19099 1/20 0.33
ROCK1 Q13464 1/20 0.33
NCEH1 Q6PIU2 1/20 0.33
BIRC5 O15392 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19781161 0.84 PIM3 (0.46) PIM3FGFR1BRD4BRPF1KMT2A
SCHEMBL1144083 0.80 CDC7 (0.44) CDC7CDK2MAP3K14KMT2AROCK1
SCHEMBL19781530 0.75 LRRK2 (0.51)
SCHEMBL19781251 0.75 FGFR1 (0.58) FGFR1CYP11B2
SCHEMBL15741202 0.75 CDC7 (0.49) CDC7CDK2MAP3K14KMT2AHTR7
SCHEMBL19781175 0.74 PTGS2 (0.39) PIM3
SCHEMBL15213070 0.73 FGFR1 (0.67) FGFR1
SCHEMBL3138547 0.72 NCEH1 (0.56) BRD4BRPF1KMT2ANCEH1
SCHEMBL1613814 0.72 CDC7 (0.54) CDC7CDK2MAP3K14ROCK1BIRC5
SCHEMBL2281906 0.70 ALDH1A3 (0.52) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2022-09-08 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
WO-2018013430-A2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220281825-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION C9, C1S, ZC3HAV1 CDC7 2238/4885CDK2 192/4885MAP3K14 3911/4885
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S CDC7 2545/4885CDK2 200/4885MAP3K14 4033/4885
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus C9, C1R, C1S CDC7 2545/4885CDK2 200/4885MAP3K14 4033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.